Nanoparticle-Based Vaccines: From Design and Immune Modulation to Clinical Translation
Pharmaceuticals and Nanotech Connect · 01.07.2026
DOI: 10.69709/pnc.2026.180808 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals and Nanotech Connect, online erschienen am 01.07.2026. Verfasst von Nada M. Elfeky und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Vaccines are one of the most notable developments in modern medicine, and their role in combating and even eradicating diseases cannot be overlooked. Through an immunological cascade, vaccines produce an immunological memory response evident by memory cells and antibodies formation. Ever since the introduction of the first vaccine against smallpox, great efforts have been made to further improve vaccine efficacy, overcome limitations, and develop vaccines against emerging pathogens. The utilization of nanotechnology in vaccines has many benefits, as nanotechnology can address most of the limitations of traditional vaccines. Moreover, it has paved the path for the development of several vaccinations and is expected to continue contributing to future advancements. Nanoparticles have several types, with each type having its advantages and drawbacks. The physicochemical characteristics of these nanoparticles, namely particle size, particle shape, particle rigidity, surface charge, and hydrophobicity, affect the immune response potency. Optimization of these properties can allow the manufacture of vaccines that trigger strong immune responses. This strategic optimization permitted the production of effective vaccine formulations against several major pathogens in the market. Notable nanoparticle vaccines include the human papillomavirus, malaria, hepatitis B, and severe acute respiratory syndrome coronavirus 2 vaccines. This comprehensive review explores the vaccine immunological cascade, the platforms of nanoparticles, their advantages and drawbacks, and the impact of their physicochemical characteristics on vaccine efficacy. Moreover, this review highlights the nanovaccine formulations that have been approved for use.
Zitieren
APA
Elfeky, N. M., Khalaf, M. G., Morsi, N. G., Fathi, H. A., Hadiya, S., Omar, O. H., Fetih, G., Kamel, S. I., & Elbadry, M. (2026). Nanoparticle-Based Vaccines: From Design and Immune Modulation to Clinical Translation. Pharmaceuticals and Nanotech Connect. https://doi.org/10.69709/pnc.2026.180808
Vancouver
Elfeky NM, Khalaf MG, Morsi NG, Fathi HA, Hadiya S, Omar OH, et al. Nanoparticle-Based Vaccines: From Design and Immune Modulation to Clinical Translation. Pharmaceuticals and Nanotech Connect. 2026. doi:10.69709/pnc.2026.180808
BibTeX
@article{Elfeky2026,
author = {Elfeky, Nada M. and Khalaf, Merna G. and Morsi, Noha G. and Fathi, Heba A. and Hadiya, Safy and Omar, Omnia H.M. and Fetih, Gihan and Kamel, Sherif I. and Elbadry, Mahmoud},
title = {Nanoparticle-Based Vaccines: From Design and Immune Modulation to Clinical Translation},
journal = {Pharmaceuticals and Nanotech Connect},
year = {2026},
doi = {10.69709/pnc.2026.180808}
}
EUVIMED